ImmuneSensor Therapeutics

ImmuneSensor Therapeutics is a biotechnology startup based in the United States, founded in 2019. The company's slogan, "Harnessing Innate Immunity to Treat Cancer & Autoimmune Disease," encapsulates its mission to develop innovative medicines targeting the cGAS-STING pathway of the innate immune system. ImmuneSensor has licensed technologies from Dr. Zhijian "James" Chen, a leading molecular biology expert at the University of Texas Southwestern Medical Center and an Investigator of the Howard Hughes Medical Institute. Dr. Chen's groundbreaking discoveries regarding cGAS and cGAMP, which activate STING to stimulate immune responses, form the basis of ImmuneSensor's technological advancement. The company's lead program, IMSA101, is currently in clinical development for cancer therapy as a STING activator. Additionally, ImmuneSensor is making strides in creating new drug candidates, including a promising cGAS inhibitor program aimed at suppressing overactivated autoimmunity. While details about their last investment and investors are not available, ImmuneSensor Therapeutics shows promise within the biotechnology, healthcare, and pharmaceutical industries with its innovative approach to addressing cancer and autoimmune diseases.